Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

ed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional Phase 3 trials planned to begin this year in both Alzheimer's disease and Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing of: initiation of clinical studies, filing of an NDA for Dimebon, seeking approval to commence a Phase 3 trial of MDV3100, the presentation of data with respect to Dimebon and MDV3100 and the receipt of milestone payments as well as the extent of future expected financial results, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of his
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... April 13 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... months ended February 28, 2009. All dollar amounts referenced herein ... 28, 2009, our cash and cash equivalents totaled $7.3 million, ... incurred a net loss for the three months ended February ...
... Decisions Day, your choice in times of despair HOUSTON, ... .( www.usoncology.com ), supporting the nation,s foremost ... and manufacturers to advance cancer care in America, is ... National Healthcare Decisions Day ( www.nationalhealthcaredecisionsday.org ...
... Kan., April 13 Kansas State University ... thin material.Vikas Berry, assistant professor of chemical engineering, is ... developed carbon material that is only a single atom ... to the next level," Berry said. "Discovered only four ...
Cached Biology Technology:Vasogen Announces First Quarter 2009 Results 2Vasogen Announces First Quarter 2009 Results 3Vasogen Announces First Quarter 2009 Results 4Vasogen Announces First Quarter 2009 Results 5Vasogen Announces First Quarter 2009 Results 6Vasogen Announces First Quarter 2009 Results 7Vasogen Announces First Quarter 2009 Results 8Vasogen Announces First Quarter 2009 Results 9US Oncology Encourages Your Right to Decide 2US Oncology Encourages Your Right to Decide 3Connecting Materials Science With Biology, K-State Engineers Create DNA Sensors That Could Identify Cancer Using Material Only One Atom Thick 2Connecting Materials Science With Biology, K-State Engineers Create DNA Sensors That Could Identify Cancer Using Material Only One Atom Thick 3
(Date:4/24/2014)... Carolina State University and the University of North Carolina ... that could help identify arterial plaque that is at ... or stroke. , At issue is the plaque that ... of plaque are deemed "vulnerable," meaning that they are ... cause heart attack or stroke. , "Existing state-of-the-art technologies ...
(Date:4/24/2014)... puts out a welcome mat to bacteria seeking to invade, ... study published this week in the Proceedings of the ... battle between microbe and host that researchers can exploit to ... oft-studied plant Arabidopsis puts out a molecular signal ... a hostile army were unknowingly passing by a castle, and ...
(Date:4/23/2014)... release is available in French and German . ... or female? In humans and other mammals, the difference between sexes ... It is present only in males, where the two sexual chromosomes ... the Y is ultimately responsible for all the morphological and physiological ... been the case. A very long time ago, the X and ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3
... 16, 2010 VaxTrac announced today that it has ... Bill & Melinda Gates Foundation. The grant will support ... Thomas, Executive Director, titled "VaxTrac Pilot Program 1 Narnaul, ... grants announced by the Gates Foundation in the fifth ...
... published Friday in the leading scientific journal, Cell , ... cells using skin cells from four individuals with Rett syndrome. ... Dr. Alysson Muotri at the University of California, San Diego--a ... The article, titled ,A Model for Neural Development and Treatment ...
... the greater Himalayan region are retreating slowly, development agencies ... prepare for the many ways glacier melt is expected ... Programs that integrate health, education, the environment and social ... report states. "The extremely high altitudes and sheer mass ...
Cached Biology News:VaxTrac Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2Researchers 'grow Rett syndrome' in a Petri dish 2Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5
The Protein Kinase Factsbooks (2 Volume Set)...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
Biology Products: